

## CURRICULUM VITAE

---

### A. Personal Experience

#### Personal Background

**Name:** Samer Loutfi Traboulsi

**Title:** Assistant Professor of Clinical Urology

**Institution:** Lebanese-American University, Gilbert and Rose-Marie Chagoury School of Medicine

**Address:** Lebanese-American University Medical Center-Rizk Hospital: Zahar street, Achrafieh, Beirut Lebanon, 11-3288  
Lebanese-American University, Byblos, Lebanon, 36  
Lebanese-American University New York Headquarters: 211 East, 46<sup>th</sup> street, New York, NY, 10017 USA

**Email 1:** samertraboulsi@hotmail.com

**Phone:** +961-3-980805

#### Languages

**Arabic** Proficient in writing and speaking

**English** Proficient in writing and speaking

**French** Proficient in writing and speaking

#### Educational Background

**June 2008** **Doctor of Medicine (MD)**  
Doctor of Medicine  
American University of Beirut

**June 2004** **Bachelor of Science (BS)**  
Bachelor of Science  
American University of Beirut

**June 2000**                      **French Baccalaureate**  
 Experimental Sciences  
 Grand Lycée Franco-Libanais

## **Training and Fellowships**

**2020**                              **Fellowship**  
 Laparoscopic Surgery  
 Clinical Fellow  
 Belgian Laparoscopy Urologic Group, Belgium  
 (February 2020 – June 2020)

**2018 - 2019**                      **Fellowship**  
 Minimally Invasive and Robotic Urologic Surgery  
 Clinical Fellow  
 University of Montreal (July 2018 – July 2019)

**2016 - 2018**                      **Fellowship**  
 Urologic Oncology  
 Clinical Fellow  
 University of Montreal (September 2016 - July 2018)

**2014 - 2016**                      **Fellowship**  
 Urology- Biology and Therapy of Urothelial Carcinoma  
 Post- Doctoral Research Fellow  
 McGill University (June 2014 - July 2016)

**2009 - 2014**                      **Residency**  
 Urology  
 Resident  
 American University of Beirut Medical Center (June 2009 - June 2014)

**2008 - 2009**                      **Internship**  
 Surgery  
 Intern  
 American University of Beirut Medical Center (June 2008 - June 2009)

**2005**                                **Clinical Clerkship**  
 Surgery  
 Elective  
 University of Wroclaw. Akademii Medycznej, Wroclaw, Poland (July 2005 - August 2005)

## Certificates and Memberships

<b>License to practice urology, Urology Specialist, License No. 10033/16, Lebanon</b>	2016 - present
<b>License to practice Medicine, General Medicine, License No. 5292/2010, Lebanon</b>	2010 - present
<b>Lebanese Order of Physicians, Lebanese Order of Physicians, No. 259/T, Lebanon</b>	2010 - present
<b>Animal Lab Training Certification</b>	2014
<b>American Urological Association member</b>	2008 - present

## Honors and Awards

<b>2016</b>	<b>UDEM scholarship (CAD 70,000)</b> University of Montreal Research Center Presented for support of the 2016-2018 Uro-Oncology fellowship. September 2016
<b>2015</b>	<b>Best Poster, moderated podium presentation</b> Northeastern Section of AUA Meeting Impact of pathology review on clinical management of patients with bladder cancer. October 2015
<b>2013</b>	<b>Award of appreciation</b> AUBMC Presented in recognition for continued support for the Resident Staff Organization for 4 years. May 2013

## Continuing Medical Education

<b>2019</b>	Rezum® water-vapor prostate ablation minimally-invasive procedure training by Boston Scientific (Pointe-Claire, QC, Canada, 2019)
<b>2018</b>	Canadian Urological Association Annual Meeting (Halifax, NS) June 2018
<b>2017</b>	Issues and Controversies in Urologic Cancer (Mont-Tremblant, Quebec) January 2017
<b>2016</b>	Quebec Urological Association Meeting (Quebec City, Quebec) November 2016
<b>2015</b>	Northeastern section of AUA meeting (Quebec City, Quebec) October 2015
<b>2015</b>	Quebec Urological Association Meeting (Montreal, Quebec) September 2015
<b>2013</b>	American Urological Association Annual Meeting (San Diego, California) May 2013
<b>2013</b>	Second Joint Uro-Oncology Winter Symposia (Beirut, Lebanon) February 2013
<b>2012</b>	Master Class review in Urology (Beirut, Lebanon) July 2012
<b>2012</b>	Surgical and Theoretical Urological Anatomy Cadaver Dissection Course (International Young Urologists Association) (Izmir, Turkey) June 2012
<b>2011</b>	Kidney Transplantation: What's New. AUB-MC in conjunction with Cleveland Clinic (Beirut, Lebanon) June 2011
<b>2010</b>	The 6th Congress of the Lebanese Society of Urology (Beirut, Lebanon) October 2010
<b>2010</b>	The 44th Middle East Medical Assembly (MEMA; Beirut, Lebanon) April 2010
<b>2009</b>	Update in Ureteroscopic Management of Ureteral and Renal Stones with Dr. Michael Grasso (AUB-MC in conjunction with the Arab Association of Urology; Beirut, Lebanon) October 2009

## B. Research

### Peer Reviewed Journal Publications

1.                   **Management of nonmetastatic castration-resistant prostate cancer**  
Traboulsi SL, Saad F  
 Current Opinion in Supportive and Palliative Care, 2018, vol.12, no.3, pp-366-371
  
2.                   **The role of bone-targeted therapies for prostate cancer in 2017**  
Traboulsi SL, Saad F  
 Current Opinion in Supportive and Palliative Care, 2017, vol.11, no.3, pp-216-224
  
3.                   **Pathology review impacts clinical management of patients with T1–T2 bladder cancer**  
Traboulsi SL, Brimo F, Yang Y, Maedler C, Prévost N, Tanguay S, Aprikian AG, Kassouf W  
 Canadian Urological Association Journal, 2017, vol.11, no.6, pp-188-193
  
4.                   **Quality indicators in the management of bladder cancer: A modified Delphi study**  
 Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Jewett M, Kulkarni G, Lacombe L, Moore R, Morash C, North S, Rendon R, Saad F, Shayegan B, Siemens R, So A, Sridhar SS, Traboulsi SL, Kassouf W  
 Urologic Oncology, 2017, vol.35, no.6, pp-328-334
  
5.                   **Contemporary management of primary distal urethral cancer**  
SL Traboulsi SL, Witjes JA, Kassouf W  
 Urologic Clinics of North America, 2016, vol.43, no.4, pp-493-503
  
6.                   **Follow-up in non-muscle invasive bladder cancer – IBCN recommendations**  
 Kassouf W, Traboulsi SL, Schmitz-Dräger B, Palou J, Witjes JA, van Rhijn BWG, Grossman HB, Kiemeney LA, Goebell P, Kamat AM  
 Urologic Oncology, 2016, vol.34, no.10, pp-460-468

- 7. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy**  
Duivenvoorden, WCM, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BWG, van de Putte EEF, Boström PJ, Koskinen I, Zareba P, Kukreja JE, Kassouf W, Traboulsi SL, Pinthus JH  
Journal of Urology, 2016, VOL.196, no.6, pp-1627-1633
- 8. Neoadjuvant chemotherapy–related histologic changes in radical cystectomy: assessment accuracy and prediction of response**  
HJ Wang, S Solanki, SL Traboulsi, W Kassouf, F Brimo  
Human Pathology, 2016, vol.53, pp-35-40
- 9. Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study**  
Florianova L, Xu B, Traboulsi S, Elmansi H, Tanguay S, Aprikian A, Kassouf W, Brimo F  
World Journal of Surgical Oncology, 2015, vol.14, pp-313-317
- 10. Bladder cancer: a step closer for individualized treatment**  
Traboulsi SL, Kassouf W  
Nature Reviews Urology, 2016, vol.13, no.3, pp-127-128
- 11. Partial versus radical nephrectomy for renal tumours ≤7 cm: the debate continues**  
Traboulsi SL, Kassouf W  
Canadian Urological Association Journal, 2015, vol.9, pp-230-231
- 12. A review of neoadjuvant and adjuvant chemotherapy for non-metastatic muscle invasive bladder cancer**  
Traboulsi SL, Kassouf W  
Urology Practice, 2016, vol.3, pp-41-49
- 13. CUA guidelines on the management of non-muscle invasive bladder cancer**  
Kassouf W, Traboulsi SL, Kulkarni GS, Breau R, Zlotta A, Fairey A, So A, Lacombe L, Rendon R, Aprikian AG, Siemens DR, Izawa JI, Black P  
Canadian Urological Association Journal, 2015, vol.9, pp-690-704
- 14. Renal angiomyxolipoma: its first appearance!**  
Traboulsi SL, Wazzan W, Abou Ghaida RR  
Urology Case Reports, 2014, vol.2, pp-89-92
- 15. Iatrogenic penile glans amputation: major novel reconstructive procedure**  
Nasr R, Traboulsi SL, Abou Ghaida RR, Bakhach J  
Case Reports in Urology, 2013, Article ID 741980

- 16. Laparoscopic Donor Nephrectomy: The Middle East Experience**  
 Khauli RB, Traboulsi SL, Medawar W, Abu Dargham R, Abdelnoor AM, Hussein MK  
 Arab Journal of Urology, 2012, vol.10, no.1, pp-46-55

## Books and Book Chapters

- 1. Management of Castration-Resistant Pca: Second-Line Therapies (Urology. Toronto (ON): Decker Medicine)**  
Traboulsi SL, Saad F  
 Online chapter (Scientific American-Urology). November 2018  
 Available at <http://www.deckered.com>
- 2. Practical Tips In Urology: Tips for Open Surgical Approach to Pelvis for Urologic Surgery (Rane, B Turna, R Autorino, JJ Rassweiler (Ed.s))**  
 El-Hout Y, Nasr R, Khater N, Traboulsi S, Khauli R.  
 Book Chapter. 2017  
 297-306, 1

## Submitted Manuscripts

**Title:** Effect diabetes and metformin on recurrence and progression in patients with non-muscle invasive bladder cancer  
**Type of Manuscript:** Article Refereed Journal  
**List of Authors in order:** Traboulsi SL, Bachir BG, Yafi FA, Bladou F, Tanguay S, Aprikian AG, Kassouf W  
**Submitted:** Yes  
**Revision following review:** Pending  
**Date of submission:** Sep 2019  
**Journal or Book:** Journal

**Title:** Functional and perioperative outcomes in elderly men after robotic-assisted radical prostatectomy for prostate cancer  
**Type of Manuscript:** Article Refereed Journal  
**List of Authors in order:** Traboulsi SL, Nguyen DD, Zakaria AS, Law K, Shahine H, Meskawi M, Negrean C, Karakiewicz P, El Hakim A, Zorn KC  
**Submitted:** Yes  
**Revision following review:** Pending  
**Date of submission:** Sep 2019  
**Journal or Book:** Journal

## Congress Abstracts and Presentations

1. **Prognostic factors in Radium-223 treatment: An early Canadian single-centre experience**  
Traboulsi S, Saad F, Taussky D, Lattouf JB, Bahary JP, Barkati M, Delouya G  
73rd Annual Meeting of the Canadian Urological Association  
Abstract- moderated poster. 2018 June
2. **Functional outcomes and postoperative complications in elderly patients (>70 years old) undergoing robotic-assisted radical prostatectomy**  
Harmouch S, Traboulsi S, Couture F, Negrean C, Mansour M, Ajib K, Tholomier C, Karakiewicz P, El-Hakim A  
73<sup>rd</sup> Canadian urological Association Annual Meeting  
Abstract- moderated poster. 2018 June
3. **Functional outcomes and post-operative complications in elderly patients (> 65 years old) undergoing robotic-assisted radical prostatectomy**  
Harmouch S, Traboulsi S, Couture F, Negrean C, Bondarenko, H, Ajib K, Tholomier C, Karakiewicz P, El-Hakim A  
33<sup>rd</sup> Annual European Association of Urology Congress  
Abstract- unmoderated poster. 2018 March
4. **Prognostic factors in Radium-223 treatment- an early Canadian single-center experience**  
Traboulsi SL, Delouya G, Taussky D, Barkati M, Bahary JP, Saad F  
American Society of Radiation Oncology Annual Meeting  
Abstract- moderated poster. 2017 September
5. **Impact of pathology review on clinical management of patients with bladder cancer**  
Traboulsi SL, Brimo F, Yang Y, Maedler C, Prévost N, Tanguay S, Aprikian AG, Kassouf W  
67<sup>th</sup> Northeastern Section of the American Urological Association Annual Meeting  
Abstract- moderated poster (***Best poster***). 2015 October
6. **Effects of diabetes and metformin on recurrence and progression in patients with non-muscle invasive bladder cancer**  
Traboulsi SL, Bachir BG, Yafi FA, Bladou F, Tanguay S, Aprikian AG, Kassouf W  
71<sup>st</sup> Canadian urological Association Annual Meeting  
Abstract- moderated **poster**. 2017 June



## Research Projects

<b>Title:</b>	The Canadian Bladder Cancer Information System (CBCIS)
<b>Role:</b>	Design, testing and implementation
<b>Period:</b>	Jun 2015 – Jun 2016
<b>Co-Investigator(s):</b>	Canada wide
<b>IRB Clearance:</b>	N/A
<b>Student Involvement Level:</b>	N/A
<b>Type of Student Involved:</b>	N/A
<b>Stage:</b>	Implemented
<b>Description:</b>	CBCIS is an electronic database platform that collects depersonalized information about current bladder cancer management practice and treatment outcomes across 14 health centers in Canada. The CBCIS aims to find answers to important questions about the clinical management of bladder cancer patients. My role was in the design of the database as a clinician and design of the interface in close association with information technology engineers. The aim is to facilitate data entry and use of the interface, automate error and inconsistency detection. I was responsible for testing the overall design workability, enter the first 150 patients at the McGill University site and verify the accuracy of data received from other medical centers. The CBCIS was implemented nationwide in 2016 and is constantly building-up
<b>Title:</b>	The Canadian High-Risk Prostate Cancer Database (CHRPC)
<b>Role:</b>	Clinical consultant
<b>Period:</b>	Oct 2016 – Jun 2018
<b>Co-Investigator(s):</b>	Canada wide
<b>IRB Clearance:</b>	N/A
<b>Stage:</b>	Implemented
<b>Description:</b>	The CHRPC is a national high-risk prostate cancer database, that collects anonymous data on patients with high-risk of recurrence prostate cancer. This database is used for research purposes and improving the management in high-risk disease
<b>Title:</b>	Tranexamic Acid During Cystectomy Trial (TACT)
<b>Role:</b>	Co-principal Investigator
<b>Period:</b>	Oct 2016 - Present
<b>Co-Investigator(s):</b>	National
<b>IRB Clearance:</b>	Yes
<b>Stage:</b>	Patient recruitment
<b>Description:</b>	Multi-center, randomized, double-blind, phase 2, placebo-controlled trial, (ClinicalTrials.gov Identifier: NCT01869413). Tranexamic acid reduces breakdown of hemostatic blood clots and has therapeutic benefits when used in other surgical procedures to reduce blood loss and the need for transfusion. The study will evaluate the efficacy and safety of tranexamic acid during radical cystectomy

**Title:** A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

**Role:** Clinical coordinator

**Period:** May 2017 - Jul 2018

**Co-Investigator(s):** Multinational

**IRB Clearance:** Yes

**Stage:** Published

**Description** Multi-center, randomized, double-blind, phase 3, placebo-controlled trial (ClinicalTrials.gov: NCT01946204). The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer

**Title:** Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms (ERA 223)

**Role:** Clinical coordinator

**Period:** Sep 2017 - Jul 2018

**Co-Investigator(s):** Multinational

**IRB Clearance:** Yes

**Stage:** Published

**Description** Multi-center, randomized, double-blind, phase 3, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT02043678) The purpose of this study is to determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs to be treated by radiotherapy

**Title:** A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

**Role:** Clinical coordinator

**Period:** Nov 2016 - Jul 2018

**Co-Investigator(s):** Multinational

**IRB Clearance:** Yes

**Stage:** Active

**Description** Multicenter, open-label study in participants with metastatic castration-resistant prostate cancer (mCRPC) ClinicalTrials.gov Identifier: NCT02123758  
The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy participants to the study. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927

**Title:** An Open-label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer  
**Role:** Clinical coordinator  
**Period:** Nov 2016 - Jul 2018  
**Co-Investigator(s):** Multinational  
**IRB Clearance:** Yes  
**Stage:** Active  
**Description** Multicenter, open-label phase 1b study in participants with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) ClinicalTrials.gov Identifier: NCT02578797  
The aim of this study is to investigate the effect of apalutamide on ventricular repolarization at a dose of level of 240 mg daily

**Title:** An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)  
**Role:** Clinical coordinator  
**Period:** Mar 2017 - Mar 2018  
**Co-Investigator(s):** Multinational  
**IRB Clearance:** Yes  
**Stage:** Active  
**Description** Multi-center, randomized, double-blind, phase 3, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT02257736)  
The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy metastatic castration-resistant prostate cancer (mCRPC)

**Title:** An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

**Role:** Clinical coordinator

**Period:** Dec 2016 - Jul 2018

**Co-Investigator(s):** Multinational

**IRB Clearance:** Yes

**Stage:** Active, recruiting

**Description** Multi-center open-label, phase 2 trial (ClinicalTrials.gov Identifier: NCT02257736)  
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration resistant prostate cancer (mCRPC) and deoxyribonucleic acid repair anomalies

**Title:** A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (QUEST).

**Role:** Clinical coordinator

**Period:** Apr 2018 - Jul 2018

**Co-Investigator(s):** Multinational

**IRB Clearance:** Yes

**Stage:** Active, recruiting

**Description** Multi-center open-label, phase 1b-2 trial (ClinicalTrials.gov Identifier: NCT03431350)  
The purpose of this study is to evaluate safety and efficacy of niraparib in combination with the anti-programmed cell death protein (PD)-1 monoclonal antibody, JNJ-63723283 (cetrelimab) in participants with metastatic castration-resistant prostate cancer (mCRPC). Another combination studied is niraparib with abiraterone acetate plus prednisone (AA-P) in mCRPC participants with DNA-repair gene defects

**Title:** A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel

**Role:** Clinical coordinator

**Period:** Nov 2016 - Sep 2018

**Co-Investigator(s):** Multinational

**IRB Clearance:** Yes

**Stage:** Active, recruiting

**Description** Multi-center randomized, double-blind, placebo controlled trial (ClinicalTrials.gov Identifier: NCT01972217)  
This is the part B of a study looking at the efficacy, safety and tolerability of the dose of olaparib selected from part A when given in addition to abiraterone, versus placebo in patients with metastatic castration-resistant prostate cancer who have received prior docetaxel treatment

**Title:** Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG

**Role:** Clinical coordinator

**Period:** Nov 2016 - Jul 2018

**Co-Investigator(s):** USA - Canada

**IRB Clearance:** Yes

**Stage:** Active

**Description** Multi-center non-randomized, open-label study (ClinicalTrials.gov Identifier: NCT02449239)  
The aim of the study is to evaluate Vicinium as an alternative to cystectomy in adults with NMIBC, specifically CIS (with or without papillary disease), high-grade Ta or any grade T1 papillary disease, who have previously failed BCG treatment (i.e., not those who are intolerant) with or without interferon

**Title:** Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET

**Role:** Clinical coordinator

**Period:** Dec 2016 - Jul 2018

**Co-Investigator(s):** Multinational

**IRB Clearance:** Yes

**Stage:** Published

**Description** Multi-center randomized control trial (ClinicalTrials.gov Identifier: NCT02449239)  
The purpose of this study is to determine the effectiveness of enzalutamide, versus a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer

**Title:** Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER).  
ClinicalTrials.gov Identifier: NCT02003924

**Role:** Clinical coordinator

**Period:** Nov 2016 - Jul 2018

**Co-Investigator(s):** Multinational

**IRB Clearance:** Yes

**Stage:** Published

**Description** Multinational phase 3 randomized double-blind placebo-controlled trial (ClinicalTrials.gov Identifier: NCT02003924)  
The aim of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer

<b>Title:</b>	CUA guidelines on the management of non-muscle invasive bladder cancer
<b>Role:</b>	Author
<b>Period:</b>	Jul 2014 - Dec 2014
<b>Co-Investigator(s):</b>	Canada wide
<b>IRB Clearance:</b>	No
<b>Stage:</b>	Published
<b>Description</b>	National guidelines for the management of superficial bladder cancer

## C. Teaching

### Mentoring

<b>2018 - 2019</b>	University of Montreal Hospital center Robotic surgical suturing skills teaching and robotic hands-on courses to surgical interns and junior residents
<b>2015 - 2016</b>	McGill University Urologic anatomy and hands-on cadaver dissection courses given to first-year medical students and surgical interns
<b>2013 - 2014</b>	American University of Beirut Introduction to benign prostate hyperplasia Lectures with updates given twice a year to second-year medical students
<b>2013 - 2014</b>	American University of Beirut Introduction to prostate cancer Lectures with updates given to twice a year to second-year medical students
<b>2012 - 2014</b>	American University of Beirut Introduction to urolithiasis Lectures with updates given twice a year to second-year medical students

<b>D. Services</b>
--------------------

**Reviewer / Editor**

**2015 - Present**            Journal of Urology  
Reviewer

**2016 - Present**            Urology Gold Journal Official Publication of the Societe Internationale  
d'Urologie  
Reviewer

**Institutional/Administrative Service**

**2012 - 2013**            Resident Staff Quality Council  
Member  
American University of Beirut Medical Center

**2011 - 2013**            Operating Room Committee member  
Member  
American University of Beirut Medical Center

**2009 - 2011**            Graduate Medical Education Committee  
Member  
American University of Beirut

**2008 - 2013**            Resident Staff Organization  
Elected Member  
American University of Beirut Medical Center

## E. References

- 1.** Assaad El-Hakim, MD, FRCSC  
Associate professor, Director of Robotic Surgery, Sacred Heart of Montreal Hospital. Tel: +1514-7588845 email: [assaad.elhakim@mcgill.ca](mailto:assaad.elhakim@mcgill.ca)
- 2.** Kevin C Zorn, MD, FRCSC, FACS  
Associate Professor, Director of Robotic Surgery, University of Montreal Hospital Center (CHUM) Tel: +1514-8908000; email: [kevin.zorn@gmail.com](mailto:kevin.zorn@gmail.com)
- 3.** Fred Saad, MD, FRCSC  
Professor and Chief of Urology and Director of GU Oncology, University of Montreal Hospital Center (CHUM) Tel: +1514-8908000; email: [fred.saad@umontreal.ca](mailto:fred.saad@umontreal.ca)
- 4.** Wassim Kassouf, MD, CM, FRCSC  
Professor and Deputy Chairman of Urology, Department of Surgery- McGill University. Tel: +1514-9348246; email: [wassim.kassouf@muhc.mcgill.ca](mailto:wassim.kassouf@muhc.mcgill.ca)
- 5.** Raja B Khauli, MD, FACS  
Professor of Surgery, Department of Surgery- American University of Beirut. Tel: +961-1-350000; Pager 0662; email: [rkhaul@aub.edu.lb](mailto:rkhaul@aub.edu.lb)
- 6.** Muhammad A Bulbul, MD, FRCSC  
Professor and Acting Head of Urology, Department of Surgery- American University of Beirut. Tel: +961-1-350000; Pager 0648; email: [mb30@aub.edu.lb](mailto:mb30@aub.edu.lb)